{'fraction_non_alphanumeric': 0.026578073089700997, 'fraction_numerical': 0.012458471760797342, 'mean_word_length': 5.548913043478261, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Antiosteoporotic activity of OST‐6(Osteocare), a herbomineral preparation in calcium deﬁcient ovariectomized rats

The preventive effect of the herbal formulation OST‐6 (Osteocare) on the progress of bone loss induced by ovariectomy and concurrent calcium deﬁciency was studied in rats. Ovariectomy (OVX) and calcium deﬁciency (CD) resulted in bone loss as evident from decreased femoral weight and density. Treatment with OST‐6 at a dose of 250 mg/kg body wt twice a day orally for a period of 16 weeks signiﬁcantly restored the femoral weight and density. The biomechanical strength of the tibia was decreased by OVX and CD and this was signiﬁcantly suppressed by the administration of OST‐6. Histologically decalciﬁed bone sections revealed narrowed, and the disappearance of, trabeculae and widened medullary spaces. The total numbers of tartrate‐resistant acid phosphates (TRAP) positive cells were increased signiﬁcantly in OVX animals. Treatment with OST‐6 signiﬁcantly inhibited these histopathological changes and strongly suggested that OST‐6 was effective in preventing the progress of bone loss induced by ovariectomy and concurrent calcium deﬁciency. Copyright © 2004 John Wiley & Sons, Ltd.